Orum Therapeutics
Focus: Orum Therapeutics is a Korea-based biotechnology company specializing in cell-penetrating antibodies targeting oncology indications. The company is in early-stage development with one Phase 1 program.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Open Jobs
4-3 this month
Stable — net -3 jobs in 30d
0 added, 3 removed. Backfill posture.
Should You Work at Orum Therapeutics?
AI assessmentOrum represents a high-risk, high-reward early-stage biotech bet best suited for scientists willing to trade stability for platform ownership in a novel modality.
Why Work Here
- Access to novel cell-penetrating antibody platform with potential to differentiate in crowded oncology space
- Early-stage opportunity to shape development of ORM-5029 (HER2+ breast cancer) and preclinical pipeline including ORM-1153 (AML)
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ORM-5029
HER2-positive Breast CancerClinical Trials (1)
NCT05511844Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Phase 1Help build intelligence for Orum Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.